AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) fell 3.2% on Thursday . The company traded as low as $3.52 and last traded at $3.64, with a volume of 237,010 shares. The stock had previously closed at $3.76.

A number of research firms have weighed in on ACRX. Stifel Nicolaus downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $7.00 price target (down previously from $9.00) on shares of AcelRx Pharmaceuticals in a research note on Tuesday, May 3rd. Cowen and Company reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, May 2nd. Seaport Global Securities upgraded shares of AcelRx Pharmaceuticals from an “accumulate” rating to a “buy” rating in a research note on Friday, May 6th. Finally, Jefferies Group restated a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, June 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $7.63.

The company’s market cap is $162.67 million. The stock has a 50-day moving average of $2.99 and a 200 day moving average of $3.32.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.02. The company earned $4.53 million during the quarter, compared to analyst estimates of $2.17 million. Analysts forecast that AcelRx Pharmaceuticals Inc. will post ($0.90) earnings per share for the current year.

In other AcelRx Pharmaceuticals news, CEO Howard B. Rosen purchased 10,206 shares of the company’s stock in a transaction that occurred on Friday, May 13th. The shares were acquired at an average price of $3.26 per share, for a total transaction of $33,271.56. Following the purchase, the chief executive officer now owns 50,000 shares in the company, valued at $163,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark G. Edwards purchased 15,000 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The stock was acquired at an average price of $3.15 per share, for a total transaction of $47,250.00. Following the purchase, the director now owns 105,000 shares in the company, valued at approximately $330,750. The disclosure for this purchase can be found here.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.